News

Enlaza Therapeutics marries covalent and biologic drugs

While they were both still at Nerio Therapeutics, Sergio Duron brought Sandy Madigan a promising paper from the laboratory of Lei Wang, a chemical biologist at the University of California, San Francisco. It described an unnatural amino acid that can turn a protein into a covalent binder.

Female Founders Social Event

UCSF Innovation Ventures Engagement & Opportunity Development and Licensing Teams organized and hosted a networking event designed to connect UCSF’s current and upcoming female founders with entrepreneurs who support them.

Minutia: Shifting the T1D Paradigm

UCSF Innovation Ventures Engagement & Opportunity Development and Licensing Teams organized and hosted a panel discussion entitled “Translating UCSF research into human therapeutics. Minutia: Shifting the T1D Paradigm on October 23, 2024.

BeeKeeperAI and Topcon Team Up to Accelerate Healthcare from the Eye

BeeKeeperAI, a pioneer in privacy-enhancing, multi-party collaboration software for artificial intelligence (AI) development and deployment, and Topcon Healthcare, a leading provider of medical devices and software solutions including advanced multi-modal imaging, vendor-inclusive data management,...

Neuvivo Seeks FDA Approval for Its Breakthrough ALS Treatment

Neuvivo, a late-clinical stage biopharmaceutical company, today announced it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for NP001 (sodium chlorite infusion) to treat amyotrophic lateral sclerosis (ALS). NP001 is an investigational treatment that, if...

Cardiology Panel Focused on the University’s Expertise

Cardiovascular disease remains the nation’s leading cause of death, and the UCSF Cardiology Department of Medicine is a pioneer in developing better ways to prevent, diagnose, and treat heart disease. Our mission is to provide the best possible care to all patients with cardiovascular disease, make...

PreludeDx Announces Groundbreaking Study Results on HER2-Positive DCIS Patients

Prelude Corporation, a leader in precision diagnostics for early-stage breast cancer, today announced the results of a cutting-edge study in Clinical Breast Cancer. The study marks a significant advancement in personalized treatment for DCIS patients. Prelude is a UCSF start-up from the lab of...

Nexilico and Siolta Therapeutics Enter Collaboration Agreement to Develop a Novel Microbiome Therapeutic for Necrotizing Enterocolitis

Nexilico, a pioneer in precision microbiome engineering, and Siolta Therapeutics, a leader in the development of live biotherapeutic products (LBPs), have entered into a collaboration agreement to address necrotizing enterocolitis (NEC) using innovative microbial therapeutics.

Neurona Therapeutics Receives $3.8 Million CIRM Grant for the Development of Next Generation Neural Cell Therapy Candidate

Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for disorders of the nervous system, today announced that the California Institute for Regenerative Medicine (CIRM) had awarded a $3.8M grant to support the development of a next-generation neural...

Venova Medical Announces $30 Million Series B Financing and Appointment of New Board Member

Venova Medical, Inc. (Venova Medical), a privately held company developing a next generation technology for the creation of percutaneous arteriovenous fistulas (pAVF) for hemodialysis access today announced the initial closing of a $30M Series B funding round.